Blu Mercury Conversations
A conversational podcast exploring the real challenges early-stage biotech companies face — from M&A data integration to product roadmapping to visual brand strategy. Hosted by Jeff Lindh.
Scientific excellence doesn't communicate itself. Every early-stage biotech faces a structural gap between the science that builds the platform and the communication that makes it legible to investors, partners, and customers. Blu Mercury founder Jeff Lindh draws on his direct experience in life sciences content strategy and visual design to explore the two disciplines that bridge the science-commercial divide.
You have the science. You have investors who believe in the vision. But do you have a roadmap — a real one? Not a slide. A structured plan that bridges scientific vision to actual operational execution. Blu Mercury founder Jeff Lindh explores why early-stage biotech startups consistently underestimate the roadmap problem, and what it looks like when a fractional PM consultant builds the product management foundation from scratch.
Most biotech acquisitions encounter data complexity post-close. The companies moving fastest conduct rigorous data discovery and mapping before closing. Learn why treating data integration as a due diligence issue — not a post-close technical problem — changes your entire integration timeline.